File Download
Supplementary
-
Citations:
- Appears in Collections:
Article: Home-based peanut oral immunotherapy for low-risk peanut-allergic preschoolers during the COVID-19 pandemic and beyond
Title | Home-based peanut oral immunotherapy for low-risk peanut-allergic preschoolers during the COVID-19 pandemic and beyond |
---|---|
Authors | |
Keywords | Peanut allergy Preschooler OIT Home Canada |
Issue Date | 2021 |
Publisher | Frontiers Media SA. The Journal's web site is located at https://www.frontiersin.org/journals/allergy |
Citation | Frontiers in Allergy, 2021, v. 2, article no. 725165 How to Cite? |
Abstract | The coronavirus disease 2019 (COVID-19) pandemic has led to the deprioritization of non-emergency services, such as oral food challenges and the initiation of oral immunotherapy (OIT) for food-allergic children. Recent studies have suggested that home-based peanut OIT could be a safe and effective option for low-risk peanut-allergic children. In the period between September 1, 2020, and January 31, 2021, nine preschoolers with a history of mild allergic reactions to peanut underwent home-based peanut OIT. Eight of them (88.9%) completed the build-up phase at home in 11–28 weeks, tolerating a daily maintenance dose of 320 mg peanut protein. During the build-up, six patients (75.0%) reported urticaria, three (33.3%) reported gastrointestinal tract symptoms, and one (14.3%) reported oral pruritis. None of the patients developed anaphylaxis, required epinephrine, or attended emergency services related to OIT. One or two virtual follow-up visits were completed per patient during the build-up phase. Our case series shows that home-based OIT could be offered to the low-risk preschoolers during the COVID-19 pandemic when non-emergency services are limited and could be considered beyond the pandemic, especially for the families living in the rural or remote areas that may otherwise be unable to access OIT. |
Persistent Identifier | http://hdl.handle.net/10722/305019 |
ISSN |
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Chua, GT | - |
dc.contributor.author | Chan, ES | - |
dc.contributor.author | Soller, L | - |
dc.contributor.author | Cook, VE | - |
dc.contributor.author | Vander Leek, TK | - |
dc.contributor.author | Mak, R | - |
dc.date.accessioned | 2021-10-05T02:38:35Z | - |
dc.date.available | 2021-10-05T02:38:35Z | - |
dc.date.issued | 2021 | - |
dc.identifier.citation | Frontiers in Allergy, 2021, v. 2, article no. 725165 | - |
dc.identifier.issn | 2673-6101 | - |
dc.identifier.uri | http://hdl.handle.net/10722/305019 | - |
dc.description.abstract | The coronavirus disease 2019 (COVID-19) pandemic has led to the deprioritization of non-emergency services, such as oral food challenges and the initiation of oral immunotherapy (OIT) for food-allergic children. Recent studies have suggested that home-based peanut OIT could be a safe and effective option for low-risk peanut-allergic children. In the period between September 1, 2020, and January 31, 2021, nine preschoolers with a history of mild allergic reactions to peanut underwent home-based peanut OIT. Eight of them (88.9%) completed the build-up phase at home in 11–28 weeks, tolerating a daily maintenance dose of 320 mg peanut protein. During the build-up, six patients (75.0%) reported urticaria, three (33.3%) reported gastrointestinal tract symptoms, and one (14.3%) reported oral pruritis. None of the patients developed anaphylaxis, required epinephrine, or attended emergency services related to OIT. One or two virtual follow-up visits were completed per patient during the build-up phase. Our case series shows that home-based OIT could be offered to the low-risk preschoolers during the COVID-19 pandemic when non-emergency services are limited and could be considered beyond the pandemic, especially for the families living in the rural or remote areas that may otherwise be unable to access OIT. | - |
dc.language | eng | - |
dc.publisher | Frontiers Media SA. The Journal's web site is located at https://www.frontiersin.org/journals/allergy | - |
dc.relation.ispartof | Frontiers in Allergy | - |
dc.rights | This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License. | - |
dc.subject | Peanut allergy | - |
dc.subject | Preschooler | - |
dc.subject | OIT | - |
dc.subject | Home | - |
dc.subject | Canada | - |
dc.title | Home-based peanut oral immunotherapy for low-risk peanut-allergic preschoolers during the COVID-19 pandemic and beyond | - |
dc.type | Article | - |
dc.identifier.email | Chua, GT: cgt560@hku.hk | - |
dc.identifier.authority | Chua, GT=rp02684 | - |
dc.description.nature | published_or_final_version | - |
dc.identifier.doi | 10.3389/falgy.2021.725165 | - |
dc.identifier.hkuros | 326434 | - |
dc.identifier.volume | 2 | - |
dc.identifier.spage | article no. 725165 | - |
dc.identifier.epage | article no. 725165 | - |
dc.publisher.place | Switzerland | - |